Evonik receives Best Bioprocessing Supplier Award for cell culture solutions
- Evonik awarded for portfolio of high-quality cell culture ingredients
- Award celebrates innovation in biopharmaceutical technologies
- Cell culture solutions are a cornerstone of Evonik’s Precision Biosolutions innovation growth area
Evonik has won in the category “Best Bioprocessing Supplier: Cell Culture Media Ingredients” in the Asia Pacific Biopharma Excellence Awards 2025. The award recognizes Evonik’s strong cell culture ingredients portfolio that includes cQrex® peptides, the plant-based cholesterol PhytoChol®, as well as R&D, formulation and process expertise. Cell culture is a key growth area for Evonik’s Health Care business.
The cell culture solutions offered by Evonik are a cornerstone to its innovation growth area “Advance Precision Biosolutions”. Customers benefit from a tailored offering of ingredients, as well as application and formulation expertise as a system solution. System solutions are multicomponent offerings across products, technologies and services that are tailored to a unique customer need and often have proven sustainability benefits.
“Receiving this award confirms that our cell culture solutions are known and appreciated by the Asia-Pacific biopharma community. It is a great honor to be recognized in this way, and we look forward to many more collaborations with companies in the region,” said Shirley Qi, President Southeast Asia, Australia & New Zealand/head of Nutrition & Care Asia Pacific at Evonik.
Winning the award for the third time in a row reflects Evonik's further development into an established system solution provider in bioprocessing. In the previous two years, the company received an award in the category Best New Bioprocessing Supplier Award: Upstream Processing; in recognition of its high-quality cell culture solutions for pharmaceutical and biotech companies.
The annual Asia-Pacific Biopharma Excellence Awards (ABEA) are organized by the global biopharmaceutical B2B and marketing intelligence company IMAPAC. The awards recognize outstanding achievements of top biopharma leaders in the industry, and drive innovation and best practices in manufacturing in the region.
“This achievement inspires us to pursue even more innovative solutions to address bioprocessing challenges in cell culture. I am thankful to everyone who has put their trust in us and look forward to working with customers on high-yield, high-quality biopharmaceuticals going forward,” said Spandan Mishra, Global Director- Technical Marketing- Biopharma Solutions at Evonik Health Care.
Evonik’s extensive portfolio of cell culture solutions combines development expertise and manufacturing capabilities to provide highly pure cell culture ingredients for use in a wide range of applications, from biopharmaceutical R&D and manufacturing to medicinal purposes.
The Health Care business line at Evonik is a global innovation hub to the world’s leading pharma and biotech companies. By leveraging six decades of industry leadership, the company provides the biopharma market with high-quality cell culture ingredients including amino acids, peptides, plant-based lipids and other non-animal-derived performance boosters.
The ABEA awards ceremony was held in conjunction with the 12th Biologics Manufacturing Asia 2025, which took place in Singapore on March 12.
Company information
Evonik is one of the world leaders in specialty chemicals. The company is active in more than 100 countries around the world and generated sales of €15.2 billion and an operating profit (adjusted EBITDA) of €2.1 billion in 2024. Evonik goes far beyond chemistry to create innovative, profitable, and sustainable solutions for customers. About 32,000 employees work together for a common purpose: We want to improve life today and tomorrow.
About Nutrition & Care
The focus of the business of the Nutrition & Care division is on health and quality of life. It develops differentiated solutions for active pharmaceutical ingredients, medical devices, nutrition for humans and animals, personal care, cosmetics, and household cleaning. In these resilient end markets, the division generated sales of €3.76 billion in 2024 with more than 5,500 employees.
Disclaimer
In so far as forecasts or expectations are expressed in this press release or where our statements concern the future, these forecasts, expectations or statements may involve known or unknown risks and uncertainties. Actual results or developments may vary, depending on changes in the operating environment. Neither Evonik Industries AG nor its group companies assume an obligation to update the forecasts, expectations or statements contained in this release.
